# EDGAR Filing Document

**Accession Number:** 0001937993
**File Stem:** 0001213900-25-125433
**Filing Date:** 2025-12
**Character Count:** 13483
**Document Hash:** 076ec268adb26c399bd226956975c94f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-125433.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001213900-25-125433

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251223

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cadrenal Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001937993
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880860746
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41596
- **FILM NUMBER:** 251601503

**BUSINESS ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 306
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082
- **BUSINESS PHONE:** 904-300-0701

**MAIL ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 306
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **December 23, 2025**

**Cadrenal Therapeutics, Inc.**

*(Exact name of registrant as specified in charter)*

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41596** | **88-0860746** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

**822 A1A North, Suite 306**

**Ponte Vedra, Florida 32082**

(Address of principal executive offices and zip code)

**(904) 300-0701**

(Registrant's telephone number including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbols** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | CVKD | **The Nasdaq Stock Market LLC**<br> **(Nasdaq Capital Market)** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On December 23, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation, (the "Company"), filed a prospectus supplement (the "Prospectus Supplement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's "at the market offering" program for the offer and sale of up to $1,770,028 of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), from time to time through H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent, pursuant to the Company's existing At the Market Offering Agreement (the "ATM Agreement"), dated March 11, 2024. As of the date hereof, the Company has sold an aggregate of $10,005,300 of shares of Common Stock pursuant to the ATM Agreement.

The offer and sale of up to $1,770,028 shares of Common Stock by the Company under the ATM Agreement is made pursuant to the Company's registration statement on Form S-3 (File No. 333-277835), initially filed with the SEC on March 12, 2024 and declared effective by the SEC on March 20, 2024 (the "Registration Statement"), and the Prospectus Supplement.

Under the ATM Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, Wainwright may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, and applicable state and federal laws. The ATM Agreement may be terminated by the Company upon written notice to Wainwright, as specified in the ATM Agreement for any reason or by Wainwright upon written notice to the Company for any reason or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company.

The ATM Agreement provides that Wainwright will be entitled to compensation for its services of 3.0% of the gross sales price of all shares sold through Wainwright under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement, and may at any time suspend solicitation and offers under the ATM Agreement. The ATM Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and Wainwright, other obligations of the parties and termination provisions.

Blank Rome LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $1,770,028 of shares of Common Stock that may be offered and sold pursuant to the ATM Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K.

The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is incorporated herein by reference as Exhibit 1.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of Common Stock discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Exhibit Description** |
| 1.1 | [At the Market Offering Agreement by and between Cadrenal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference as Exhibit 1.1 to the Current Report on Form 8-K filed on March 12, 2024)](http://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/ea020152401ex1-1_cadrenal.htm) |
| 5.1 | [Opinion of Blank Rome LLP](ea027090801ex5-1_cadrenal.htm) |
| 23.1 | [Consent of Blank Rome LLP (included in Exhibit 5.1)](ea027090801ex5-1_cadrenal.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: December 23, 2025 | CADRENAL THERAPEUTICS, INC. | CADRENAL THERAPEUTICS, INC. |
|  | By: | /s/ Quang X. Pham |
|  | Name: | Quang X. Pham |
|  | Title: | Chairman and Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

1271 Avenue of the Americas \| New York, NY 10020

blankrome.com

December 23, 2025

The Board of Directors

Cadrenal Therapeutics, Inc.

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

**Re:** **Cadrenal Therapeutics, Inc.**

Dear Ladies and Gentlemen:

We have acted as counsel to Cadrenal Therapeutics, Inc., a Delaware corporation (the "**Company**"), in connection with a prospectus supplement, dated December 23, 2025 (the "**Prospectus Supplement**"), to the base prospectus (the "**Base Prospectus**"), dated March 20, 2024, that forms a part of the Registration Statement on Form S-3 (Registration No. 333-277835) (the "**Registration Statement**") initially filed by the Company on March 12, 2024 under the Securities Act of 1933, as amended (the "**Securities Act**"), with the U.S. Securities and Exchange Commission (the "**Commission**"), and declared effective on March 20, 2024, relating to the offering of up to $1,770,028 of shares (the "**Shares**") of the Company's common stock, par value $0.001 per share (the "**Common Stock**"). The Shares are to be sold, if any, by the Company pursuant to that certain At the Market Offering Agreement, dated March 11, 2024 (the "**ATM Sales Agreement**"), by and between the Company and H.C. Wainwright & Co., LLC ("Wainwright" or the "sales agent").

In our capacity as counsel to the Company, we have examined the original or certified copies of such records of the Company and such agreements, certificates of public officials, certificates of officers or representatives of the Company and others, and such other documents as we deem relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed, without inquiry, the legal capacity of all natural persons, the genuineness of all signatures on all documents examined by us, the authenticity of all documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as copies and the authenticity of the originals of such latter documents. We have also assumed that the books and records of the Company are maintained in accordance with proper corporate procedures. As to various questions of fact material to such opinion, we have relied upon statements or certificates of officials and representatives of the Company and others.

We have assumed (i) that each sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section 152 of the Delaware General Corporation Law, (ii) at the time of issuance of any Shares, there shall be a sufficient number of duly authorized and unissued shares of Common Stock to accommodate the issuance of the Shares, and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Common Stock. We express no opinion to the extent that future issuances of securities of the Company, anti-dilution adjustments to outstanding securities of the Company and/or other matters cause the number of shares of the Common Stock available for issuance under the ATM Sales Agreement to exceed the number of shares of the Common Stock available for issuance by the Company.

Based upon the foregoing, it is our opinion that, that the Shares, when sold and issued against payment therefor in accordance with the ATM Sales Agreement, will be validly issued, fully paid and nonassessable.

We are opining solely on all applicable statutory provisions of Delaware corporate law, including the rules and regulations underlying those provisions, all applicable provisions of the Delaware Constitution and all applicable judicial and regulatory determinations. This opinion is limited to the laws of the State of Delaware as in effect on the date hereof and we express no opinion with respect to the laws of any other jurisdiction. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we undertake no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

![](ex5-1_001.jpg)

The Board of Directors

Cadrenal Therapeutics, Inc.

December 23, 2025

We also hereby consent to the use of our name as your counsel under "Legal Matters" in the Prospectus Supplement and the filing of this opinion as Exhibit 5.1 to a Current Report on Form 8-K of the Company to be filed on the date hereof and the incorporation by reference of this opinion in the Registration Statement. In giving this consent, we do not thereby concede that we come within the categories of persons whose consent is required by the Securities Act or the General Rules and Regulations promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ BLANK ROME |
| BLANK ROME LLP |

---

Blank Rome LLP \| blankrome.com